✦ LIBER ✦

CN5 EXPLORATORY ECONOMIC EVALUATION OF ADJUVANT TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC) WITH BEVACIZUMAB IN ADDITION TO A CISPLATIN-BASED TREATMENT REGIMEN IN THE UNITED KINGDOM

✍ Scribed by M Gyldmark; U Gatzemeier; M Nicolson; N Latimer; S Walzer

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Economic evaluation of Gemzar/cisplatin

✍ N. Botwood; J. McKendrick; M. Aristides; M. Lees; N. Maniadakis; W. Wein; D. Ste 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 191 KB

Preliminary results of a randomised phas

✍ Costa, A; Barradas, P; Cristóvão, M; Alves, P; Melo, M.J 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 111 KB

9149 Phase II study of bevacizumab in co

✍ Ferrer, N.; Cobo, M.; Paredes, A.; Méndez, M.; Muñoz-Langa, J.; Rueda, A.; de Mo 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

6 A phase III randomized trial evaluatin

✍ Sculier, J.P.; Paesmans, M.; Thiriaux, J.; Bureau, G.; Giner, V.; Efremidis, A.; 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 152 KB

PCN87 A COST-EFFECTIVENESS ANALYSIS OF B

✍ HG Bischoff; D Heigener; C Wiesner; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

A phase II study with vinorelbine, gemci

✍ Ginopoulos, P.; Mastronikolis, N.S.; Giannios, J.; Karana, A.; Siabi, V.; Karvel 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 77 KB